Brief: Alpha Cognition Inc - On Track And Plans To Release Data From Alpha-1062 Pivotal Trial During Q2 Of 2022
31/05/2022 13:34
May 31 (Reuters) - Alpha Cognition Inc ACOG.V :
* ALPHA COGNITION INC - ON TRACK AND PLANS TO RELEASE DATA
FROM
ALPHA-1062 PIVOTAL TRIAL DURING Q2 OF 2022
* ALPHA COGNITION INC - PLANS TO MEET WITH FDA FOR
ALPHA-1062
INTRANASAL FOR MTBI DURING Q3 OF 2022
* ALPHA COGNITION INC - Q1 2022 NET LOSS WAS $2.7 MILLION,
OR A
NET LOSS OF $0.04 PER SHARE
* ALPHA COGNITION INC - CASH, CASH EQUIVALENTS AS OF MARCH
31,
2022, WERE $9.1 MILLION
Source text for Eikon: ID:nBw2kCFj7a
Further company coverage: ACOG.V
Recent news on Alpha Cognition
See all newsBrief: Alpha Cognition Announces Pricing Of $50 Million Upsized Public Offering And Nasdaq Listing
Brief: Alpha Cognition Inc - Files Registration Statement For $25 Million Offering
Brief: Alpha Cognition Announces Completion Of $4.545 Million Convertible Note And Warrants Bridge Financing
Brief: Alpha Cognition Says On Track To Secure Financing For Continued Growth
Brief: Alpha Cognition Inc Says Applied To List Common Shares On Nasdaq Under Trading Symbol “Acog”